PMID- 38273845
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240128
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - Non-small cell lung cancer with MET amplification: review of epidemiology, 
      associated disease characteristics, testing procedures, burden, and treatments.
PG  - 1241402
LID - 10.3389/fonc.2023.1241402 [doi]
LID - 1241402
AB  - INTRODUCTION: Mesenchymal-epidermal transition factor gene amplification (METamp) 
      is being investigated as a therapeutic target in advanced non-small cell lung 
      cancer (NSCLC). We reviewed the epidemiology and disease characteristics 
      associated with primary and secondary METamp, as well as the testing procedures 
      used to identify METamp, in advanced NSCLC. Economic and humanistic burdens, and 
      the practice patterns and treatments under investigation for METamp were also 
      examined. METHODS: Embase and Medline (via ProQuest), ClinicalTrials.gov, and 
      Cochrane Controlled Register of Trials (2015-2022) were systematically searched. 
      Conference abstracts were searched via Embase and conference proceedings websites 
      (2020-2022). The review focused on evidence from the United States; global 
      evidence was included for identified evidence gaps. RESULTS: The median rate of 
      primary METamp in NSCLC across the references was 4.8% (n=4 studies) and of 
      secondary METamp (epidermal growth factor receptor [EGFR]-mutant NSCLC) was 15% 
      (n=10). Next-generation sequencing (NGS; n=12) and/or fluorescence in situ 
      hybridization (FISH; n=11) were most frequently used in real-world studies and 
      FISH testing most frequently used in clinical trials (n=9/10). METamp definitions 
      varied among clinical trials using ISH/FISH testing (MET to chromosome 7 
      centromere ratio of >/=1.8 to >/=3.0; or gene copy number [GCN] >/=5 to >/=10) and among 
      trials using NGS (tissue testing: GCN >/=6; liquid biopsy: MET copy number >/=2.1 to 
      >5). Limited to no data were identified on the economic and humanistic burdens, 
      and real-world treatment of METamp NSCLC. Promising preliminary results from 
      trials enrolling patients with EGFR-mutated, METamp advanced NSCLC progressing on 
      an EGFR-tyrosine kinase inhibitor (TKI) were observed with MET-TKIs (i.e., 
      tepotinib, savolitinib, and capmatinib) in combination with EGFR-TKIs (i.e., 
      gefitinib and osimertinib). For metastatic NSCLC and high-level METamp, 
      monotherapy with capmatinib, crizotinib, and tepotinib are recommended in the 
      2022 published NSCLC NCCN Guidelines. CONCLUSION: Primary METamp occurs in 
      approximately 5% of NSCLC cases, and secondary METamp in approximately 15% of 
      cases previously treated with an EGFR inhibitor. Variability in testing methods 
      (including ISH/FISH and NGS) and definitions were observed. Several treatments 
      are promising in treating METamp NSCLC. Additional studies evaluating the 
      clinical, economic, and humanistic burdens are needed.
CI  - Copyright (c) 2024 Yang, Mandal, Liu, O'Hara, Lesher and Sanborn.
FAU - Yang, Mo
AU  - Yang M
AD  - North America Evidence and Value Development, North America Medical Affairs, EMD 
      Serono, Inc., Rockland, MA, United States, an affiliate of Merck KGaA.
FAU - Mandal, Erin
AU  - Mandal E
AD  - Evidence and Access, OPEN Health, Parsippany, NJ, United States.
FAU - Liu, Frank X
AU  - Liu FX
AD  - North America Evidence and Value Development, North America Medical Affairs, EMD 
      Serono, Inc., Rockland, MA, United States, an affiliate of Merck KGaA.
FAU - O'Hara, Richard M Jr
AU  - O'Hara RM Jr
AD  - North America Evidence and Value Development, North America Medical Affairs, EMD 
      Serono, Inc., Rockland, MA, United States, an affiliate of Merck KGaA.
FAU - Lesher, Beth
AU  - Lesher B
AD  - Evidence and Access, OPEN Health, Parsippany, NJ, United States.
FAU - Sanborn, Rachel E
AU  - Sanborn RE
AD  - Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, 
      United States.
LA  - eng
PT  - Systematic Review
DEP - 20240111
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC10808753
OTO - NOTNLM
OT  - epidemiology
OT  - epithelial-mesenchymal transition
OT  - non-small cell lung carcinoma
OT  - systematic review
OT  - treatment outcome
COIS- Authors MY, FL, and RH were employed by the company EMD Serono, Inc., Rockland, 
      MA, USA, an affiliate of Merck KGaA, at the time of the study. Authors EM and BL 
      were employed by the company OPEN Health at the time of this study, which was the 
      recipient of consulting fees from EMD Serono, Inc., Rockland, MA, USA, an 
      affiliate of Merck KGaA. Author RS received honoraria from AstraZeneca, and 
      Amgen; attended advisory boards and provided consulting for AstraZeneca, EMD 
      Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Daiichi Sankyo, 
      Lilly, Janssen Oncology, Macrogenics, Sanofi/Aventis, Regeneron, Mirati 
      Therapeutics, and GlaxoSmithKline; received research funding from Merck, 
      AstraZeneca Investigator-sponsored trials, and BMS Institution research funding.
EDAT- 2024/01/26 06:43
MHDA- 2024/01/26 06:44
PMCR- 2023/01/01
CRDT- 2024/01/26 03:43
PHST- 2023/06/16 00:00 [received]
PHST- 2023/11/27 00:00 [accepted]
PHST- 2024/01/26 06:44 [medline]
PHST- 2024/01/26 06:43 [pubmed]
PHST- 2024/01/26 03:43 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1241402 [doi]
PST - epublish
SO  - Front Oncol. 2024 Jan 11;13:1241402. doi: 10.3389/fonc.2023.1241402. eCollection 
      2023.